Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (61)	7/10/2000 10:09:26 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 598

Tuck: Just the recent past, heading into lockup and the Novartis deal. TLRK is one of the class acts in small molecules, with a diversified program. I'm not suggesting that one look at anything other than what you've already highlighted. I always seek out an "anchor" for valuation, a relatively mature business plan. I then try to get a feel for whether or not the anchor is fairly valued. In this case, I sort of like the current valuation for VRTX.... not too high, certainly not significantly discounted (sales stink). Then I sort of feel around the breadth of research programs and the excellence of science. Both companies are as good as it gets. So.... is the maturity of the VRTX program worth 2-3X (current situation) that of TLRK? Probably. Is it worth 10X? No, the TLRK business plan will mature rapidly, if and when it matures. Don't bet against Goeddel et al. >> once in a while I manage to post proper research. << Unless you're 80, no hurry. If one takes the time to learn valuation in biotech, idiots will present you will op after op. Thanks for taking the time to study this one, one of the most exiting of biotechs. Rick